‘DrugAbacus’ Pricing Tool Helps Payers Calculate Fair Value Of Cancer Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
Memorial Sloan Kettering’s Peter Bach unveils a web-based drug pricing tool that uses several value measurements, including R&D investment and novelty, to identify the appropriate price for cancer drugs.
You may also be interested in...
As Drug Value Frameworks Gain Traction, Patients Seek More Input
'Patients are ready and willing to have conversations' about trade-offs, National Health Council's Perfetto says.
Medicare Part D Coverage For Obesity Drugs Urged By House Appropriations Panel
In the report accompanying FY 2023 HHS appropriations legislation, the House committee also addresses biosimilar uptake in Part D, Medicare dispensing fees for oral COVID-19 drugs and NIH grants for expanded access to investigational ALS drugs.
Senate Insulin Bill Focuses On List Prices With Carrot For Manufacturers, Stick For PBMs
US legislation attempts to address manufacturer, pharmacy benefit manager impact on patient costs in addition to health plan benefit designs. Critics suggest it’s too easy on manufacturers but that may help its chances with Republicans.